Novo Nordisk (NVO) Trailing P/Es: LLY 38, NOV 10 Forward P/Es: LLY 26, NVO 11 Estimated 2026 sales growth: LLY 26%, NVO -8% Estimated 2025 EPS growth: LLY 43%, NVO -6% Cash per share: LLY $8.14, NVO $6.07 Institutional ownership: LLY 84.6%, NVO 9.5% In terms of value, NVO has LLY beat by a mile, trading at less than a third of LLY on a trailing price-to-earnings basis and just under half of it on a forward price-to-earnings basis
Supplements are designed to "supplement" a healthy lifestyle, not replace it
Frequent missed doses do reduce effectiveness, so work on strategies to improve adherence if this becomes a pattern
review with your clinician if pregnant or managing liver conditions 3
Sponsored Content Copper peptide GHK-Cu: A natural compound with potentially far-reaching benefits Published 1:00 pm Monday, March 31, 2025 Copper peptide GHK-Cu has garnered recent attention in skincare and regenerative medicine for its potential to support skin health and repair
